Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 4.77

(5.54%)

Long Term Debt Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual long term debt in 2024 was 190.93 Million USD , up 2.06% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly long term debt in 2024 FY was 190.93 Million USD , down -2.82% from previous quarter.
Xeris Biopharma Holdings, Inc. reported annual long term debt of 196.47 Million USD in 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported annual long term debt of 196.47 Million USD in 2022, up 123.1% from previous year.
Xeris Biopharma Holdings, Inc. reported quarterly long term debt of 190.93 Million USD for 2024 Q2, up 0.27% from previous quarter.
Xeris Biopharma Holdings, Inc. reported quarterly long term debt of 190.93 Million USD for 2024 FY, down -2.82% from previous quarter.

Annual Long Term Debt Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Long Term Debt of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Long Term Debt	Long Term Debt Growth
2024	190.93 Million USD	2.06%
2023	196.47 Million USD	0.0%
2022	196.47 Million USD	123.1%
2021	88.06 Million USD	1.2%
2020	87.02 Million USD	172.88%
2019	31.89 Million USD	0.0%
2018	- USD	0.0%
2017	- USD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q3	229.67 Million USD	20.29%
2024 Q2	190.93 Million USD	0.27%
2024 FY	190.93 Million USD	-2.82%
2024 Q1	225.57 Million USD	1.19%
2024 Q4	230.48 Million USD	0.35%
2023 Q3	196.96 Million USD	-11.69%
2023 Q4	223.05 Million USD	13.24%
2023 FY	196.47 Million USD	0.0%
2023 Q1	138.5 Million USD	0.32%
2023 Q2	223.05 Million USD	61.04%
2022 Q4	138.06 Million USD	0.31%
2022 FY	196.47 Million USD	123.1%
2022 Q3	137.63 Million USD	56.29%
2022 Q2	88.06 Million USD	0.4%
2022 Q1	87.71 Million USD	0.27%
2021 Q4	87.47 Million USD	0.24%
2021 Q1	119.39 Million USD	9.06%
2021 Q2	87.02 Million USD	-27.11%
2021 Q3	87.27 Million USD	0.29%
2021 FY	88.06 Million USD	1.2%
2020 FY	87.02 Million USD	172.88%
2020 Q3	58.48 Million USD	0.31%
2020 Q2	58.3 Million USD	0.31%
2020 Q1	58.12 Million USD	97.68%
2020 Q4	109.47 Million USD	87.19%
2019 Q1	31.64 Million USD	74.17%
2019 FY	31.89 Million USD	0.0%
2019 Q4	29.4 Million USD	-8.52%
2019 Q3	32.14 Million USD	0.79%
2019 Q2	31.89 Million USD	0.78%
2018 Q2	- USD	0.0%
2018 Q4	18.16 Million USD	0.64%
2018 FY	- USD	0.0%
2018 Q3	18.05 Million USD	0.0%
2017 Q3	- USD	0.0%
2017 FY	- USD	0.0%

Peer Long Term Debt Comparison of Xeris Biopharma Holdings, Inc.

Name	Long Term Debt	Long Term Debt Difference
Arrowhead Pharmaceuticals, Inc.	104.6 Million USD	-82.521%
Codexis, Inc.	12.24 Million USD	-1459.52%
Viridian Therapeutics, Inc.	20.2 Million USD	-844.974%
Organovo Holdings, Inc.	888 Thousand USD	-21401.351%